Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12415–12425 | Cite as

Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia

  • Bin Li
  • Lili Wan
  • Yan Li
  • Qi Yu
  • Pengguo Chen
  • Run Gan
  • Quanjun Yang
  • Yonglong Han
  • Cheng Guo
Research Article

Abstract

Inflammatory responses are key contributors to cancer cachexia and foster a complex cascade of biological outcomes. Baicalin is a natural compound derived from Scutellaria baicalensis that possesses anti-inflammatory properties in many diseases; therefore, the aim of this study was to verify whether baicalin could ameliorate cachexia in a CT26 adenocarcinoma-induced model. Tumour-bearing and control mice were injected with CT26 adenocarcinoma cells and phosphate-buffered saline (PBS), respectively, and baicalin was administered intraperitoneally for 15 days. During the study, food intake, body weight, major organ weight, gastrocnemius muscle weight, tibialis muscle weight, epididymal fat weight and serum cytokine levels were measured and evaluated. Additionally, the expression of two E3 ubiquitin ligases and NF-κB pathway proteins were detected by Western blot. The total food intake in tumour-bearing mice receiving baicalin from days 1–16, as well as the average food intake on days 10–16, were less than normal but were significantly higher than in vehicle-treated tumour-bearing mice. Loss of tumour-free body mass in vehicle-treated tumour-bearing mice was significantly increased compared with control mice and tumour-bearing mice receiving baicalin. Serum cytokines, including tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), were lowered in tumour-bearing mice treated with baicalin. Gastrocnemius muscle, epididymal fat, heart and kidney weight were significantly greater in the baicalin treatment groups compared with the vehicle-treated tumour-bearing mice. In addition, the expression of two E3 ubiquitin ligases, as well as phospho-p65, was significantly downregulated, whereas the expression of IκBα was up-regulated in tumour-bearing mice treated with baicalin, as determined by Western blotting. The present study demonstrates that baicalin effectively ameliorates anorexia by inhibiting cytokine expression and prevents skeletal muscle atrophy most likely by inhibiting activation of NF-κB in an experimental cancer cachexia model, suggesting that baicalin represents a promising natural medicine for treating cancer-induced cachexia.

Keywords

Baicalin Cachexia Body mass Skeletal muscle atrophy Anorexia 

Notes

Acknowledgments

This study was supported by study project grants from the National Natural Science Foundation of China (Grant No. 81072687) and the Polytechnic Crossing Project, Shanghai Jiao Tong University. All works were completed at the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Conflict of interest

None.

References

  1. 1.
    Argilés JM, Anker SD, Evans WJ, et al. Consensus on cachexia definitions. J Am Med Dir Assoc. 2010;11:229–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior tochemotherapy in cancer patients. Am J Med. 1980;69:491–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003;11:652–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000;1:138–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ Br Med J. 1997;315:1219.CrossRefGoogle Scholar
  7. 7.
    Skipworth RJ, Stewart GD, Dejong CH, et al. Pathophysiology of cancer cachexia: much more than host–tumour interaction? Clin Nutr. 2007;26:667–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381–410.PubMedCrossRefGoogle Scholar
  10. 10.
    Argilés JM, Busquets S, López-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005;37:2036–46.PubMedCrossRefGoogle Scholar
  11. 11.
    Argilés JM, Busquets S, Moore-Carrasco R, et al. The role of cytokines in cancer cachexia. In Cachexia and wasting: a modern approach. Springer 2006; 467–475.Google Scholar
  12. 12.
    Noguchi Y, Yoshikawa T, Matsumoto A, et al. Are cytokines possible mediators of cancer cachexia? Surg Today. 1996;26:467–75.PubMedCrossRefGoogle Scholar
  13. 13.
    Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13:225–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci. 2001;98:14440–5.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Cao PR, Kim HJ, Lecker SH. Ubiquitin–protein ligases in muscle wasting. Int J Biochem Cell Biol. 2005;37:2088–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Cai DS, Feantz JD, Tawa NE, et al. IKK/NF-B activation causes severe muscle wasting in mice. Cell. 2004;119:285–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Srinivas N. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica. 2010;40:357–67.PubMedCrossRefGoogle Scholar
  20. 20.
    Hou J, Wang J, Zhang P, et al. Baicalin attenuates proinflammatory cytokine production in oxygen–glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway. Int Immunopharmacol. 2012;14:749–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang N, Van Crombruggen K, Holtappels G, et al. A herbal composition of Scutellaria baicalensis and Eleutherococcus senticosus shows potent anti-inflammatory effects in an ex vivo human mucosal tissue model. Evidence-based complementary and alternative medicine 2012; 2012.Google Scholar
  22. 22.
    Zhang XP, Feng GH, He JX, et al. Baicalin protects thymus of rats with severe acute pancreatitis. Inflammation. 2010;33:157–65.CrossRefGoogle Scholar
  23. 23.
    Lim HA, Lee EK, Kim JM, et al. PPARγ activation by baicalin suppresses NF-κB-mediated inflammation in aged rat kidney. Biogerontology. 2012;13:133–45.PubMedCrossRefGoogle Scholar
  24. 24.
    Li L, Bao H, Wu JF, et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: a possible role for HDAC2 activity. Int Immunopharmacol. 2012;13:15–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Zeng LX, Dong JC, Yu WQ, et al. Baicalin attenuates inflammation by inhibiting NF-κB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther. 2010;23:411–9.CrossRefGoogle Scholar
  26. 26.
    Tanaka Y, Eda H, Tanaka T, et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290–5.PubMedGoogle Scholar
  27. 27.
    Murphy KT, Chee A, Trieu J, et al. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech. 2012;5:533–45.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Acharyya S, Butchbach ME, Wang HT, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8:421–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Radbruch L, Elsner F, Trottenberg P, et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicinen/European Palliative Care Research Collaborative; 2010.Google Scholar
  30. 30.
    Yae S, Takahashi F, Yae T, et al. Hochuekkito (TJ-41), A Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice. Evidence-based complementary and alternative medicine 2012; 2012: Article ID 976926, 10 pages.Google Scholar
  31. 31.
    Shadfar S, Couch ME, McKinney KA, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011;63:749–62.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Yang QJ, Wang LL, Zhou ZY, et al. Parthenolide from Parthenium integrifolium reduces tumor burden and alleviate cachexia symptoms in the murine CT-26 model of colorectal carcinoma. Phytomedicine. 2013;20:992–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Tranmer JE, Heyland D, Dudgeon D, et al. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag. 2003;25:420–9.CrossRefGoogle Scholar
  34. 34.
    Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999;59:4493–501.PubMedGoogle Scholar
  35. 35.
    Fearon KC. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1992;51:251–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Mary G, Rhoads SCK, Fabio P, Doglietto GB, et al. Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer. 2010;46(1):191–7.CrossRefGoogle Scholar
  37. 37.
    Chen WC, Kuo TH, Tzeng YS, et al. Baicalin induces apoptosis in SW620 human colorectal carcinoma cells in vitro and suppresses tumor growth in vivo. Molecules. 2012;17:3844–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Qiu JZ, Niu XD, Dong J, et al. Baicalin protects mice from staphylococcus aureus pneumonia via inhibition of the cytolytic activity of α-hemolysin. J Infect Dis. 2012;206:292–301.PubMedCrossRefGoogle Scholar
  39. 39.
    Wan QF, Wang H, Han XB, et al. Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus. Biomed Reports. 2014;2:437–41.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Bin Li
    • 1
    • 2
    • 3
  • Lili Wan
    • 1
  • Yan Li
    • 1
  • Qi Yu
    • 1
  • Pengguo Chen
    • 1
  • Run Gan
    • 1
    • 3
  • Quanjun Yang
    • 1
  • Yonglong Han
    • 1
  • Cheng Guo
    • 1
    • 3
  1. 1.Department of PharmacyShanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghaiPeople’s Republic of China
  2. 2.Department of Integrative OncologyBenxi Central HospitalBenxiPeople’s Republic of China
  3. 3.Graduate SchoolShanghai University of Traditional Chinese MedicineShanghaiPeople’s Republic of China

Personalised recommendations